Skip to main
MNMD
MNMD

MNMD Stock Forecast & Price Target

MNMD Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 54%
Buy 46%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Mind Medicine Inc. is developing innovative product candidates addressing brain health disorders, with a strong focus on MM120 and MM402 that target significant neurotransmitter pathways. The positive outcomes from clinical trials for MM120, including substantial improvements in anxiety and depressive symptoms, have led to its designation as a Breakthrough Therapy by the FDA, which may expedite its pathway to commercialization. Additionally, the drug's demonstrated ability to enhance quality of life, coupled with its favorable tolerance profile and evidence of sustained efficacy, underscores the potential for Mind Medicine to capture a significant portion of the treated market in mental health therapies.

Bears say

Mind Medicine Inc. is developing innovative product candidates, such as MM120 and MM402, aimed at addressing significant mental health disorders, including generalized anxiety disorder and autism spectrum disorder. However, there are indications of limited efficacy at lower doses for MM120, raising concerns about its overall therapeutic viability and market potential. Additionally, projected funding needs from 2025 to 2027, totaling $150 million, could lead to dilution of existing shareholders, further exacerbating investor hesitance amid uncertain clinical outcomes.

MNMD has been analyzed by 13 analysts, with a consensus rating of Buy. 54% of analysts recommend a Strong Buy, 46% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Mind Medicine MindMed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Mind Medicine MindMed (MNMD) Forecast

Analysts have given MNMD a Buy based on their latest research and market trends.

According to 13 analysts, MNMD has a Buy consensus rating as of Jul 27, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20.54, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20.54, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Mind Medicine MindMed (MNMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.